All In Biotech

Drug Trial Radar · NCT03277105

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 522 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

522

Actual

Start

Oct 27, 2017

Primary completion

Jun 27, 2019

Study completion Jan 12, 2024

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).

Conditions

  • Multiple Myeloma

Interventions

  • Dara SCDrug

    Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.

  • Dara IVDrug

    Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to 1 year 8 months
  2. Maximum Trough Concentration (Ctrough) of DaratumumabTime frame: Predose on Cycle 3 Day 1 (each cycle of 28 days)

Locations

146 sites in 18 countries. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Alfred Health

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • The Queen Elizabeth Hospital

    Woodville South, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Fundacao Pio XII

    Barretos, Brazil

  • Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN

    Florianópolis, Brazil

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil

  • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia

    Joinville, Brazil

  • Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo

    Passo Fundo, Brazil

  • Hospital das Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude

    Rio de Janeiro, Brazil

  • CEHON

    Salvador, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base

    São José do Rio Preto, Brazil

  • Clinica Sao Germano

    São Paulo, Brazil

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, Brazil

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • The Gordon & Leslie Diamond Health Care Center

    Vancouver, British Columbia, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Victoria Hospital

    London, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • CHU de Quebec L Hotel Dieu de Quebec

    Québec, Quebec, Canada

  • Fakultni nemocnice Brno

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia

  • Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni

    Pilsen, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie

    Prague, Czechia

  • CHU Caen - Côte de Nacre

    Caen, France

  • Hopital Claude Huriez

    Lille, France

  • CHU de Nantes hotel Dieu

    Nantes, France

  • CHU de Boreaux

    Pessac, France

  • Centre hospitalier Lyon-Sud

    Pierre-Bénite, France

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.